Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6223]
In development
Reference number: GID-TA11232
Expected publication date:
Following the committee meeting on 20 November 2025 further work is being conducted and the expected publication date has been amended.